![Maya Lalive d‘Epinay](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Maya Lalive d‘Epinay first degree
Entity | Entity type | Industry | |
---|---|---|---|
Redalpine Venture Partners AG
![]() Redalpine Venture Partners AG Investment ManagersFinance Redalpine Venture Parners AG (Redalpine) is an independent venture capital investment firm headquartered in Zurich, Switzerland. The firm was founded in 2006.
1
| Private Company | Investment Managers | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Maya Lalive d‘Epinay via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Merck Ventures BV
![]() Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
Indi Molecular, Inc.
![]() Indi Molecular, Inc. BiotechnologyHealth Technology Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA. | Biotechnology | Director/Board Member | |
University of Innsbruck | College/University | Graduate Degree | |
University of Zurich | College/University | Doctorate Degree | |
Lundbeckfonden Emerge
![]() Lundbeckfonden Emerge Investment ManagersFinance Lundbeckfonden Emerge (Emerge) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2012 and is headquartered in Copenhagen, Denmark. | Investment Managers | Private Equity Investor | |
ImmunOs Therapeutics AG
![]() ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | Biotechnology | Director/Board Member | |
Mediar Therapeutics, Inc.
![]() Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member |
Statistics
International
United States | 3 |
Switzerland | 3 |
Netherlands | 2 |
Austria | 2 |
Denmark | 2 |
Sectoral
Health Technology | 4 |
Finance | 3 |
Consumer Services | 3 |
Operational
Director/Board Member | 3 |
Private Equity Investor | 2 |
Private Equity Analyst | 1 |
Graduate Degree | 1 |
Doctorate Degree | 1 |
Most connected contacts
Insiders | |
---|---|
Andreas Jurgeit | 8 |
- Stock Market
- Insiders
- Maya Lalive d‘Epinay
- Company connections